TYME - Major Catalysts Ahead: 1) SM-88 Poster At ASCO 2021, 2) Results Of Strategic Review June 10. Game-Changing Oncology Platform (NASDAQ:TYME) | Seeking Alpha
Summary of randomized clinical trials in cardiovascular diseases with... | Download Table
SM-88 Moves Forward in HopES Sarcoma Trial
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer | SpringerLink
TYME Inc. - Data Publications - Scientific Presentations
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design - ScienceDirect
TYME Inc. - Our Science - SM-88 Overview
Weill Cornell GI Oncology Program - Dr. Allyson Ocean will lead a phase two clinical trial of SM-88 for advanced pancreatic cancer patients at Weill Cornell Medicine and NewYork-Presbyterian. Research behind this
TYME Presents New Preclinical Data Supporting SM-88 Mechanism of Action at AACR 2020 | Business Wire
EX-99.1
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer | SpringerLink
EX-99.2
EX-99.1
TYME - Major Catalysts Ahead: 1) SM-88 Poster At ASCO 2021, 2) Results Of Strategic Review June 10. Game-Changing Oncology Platform (NASDAQ:TYME) | Seeking Alpha
TYME To Make An Impact
TYME's Novel Metabolic-Based Cancer Therapy, SM-88,
Step Counts Correlated With QoL With SM-88 in Metastatic Pancreatic Cancer
Ocean Outlines Promise of SM-88 in Advanced Pancreatic Cancer
TYME Technologies Inc - SM-88 Pancreatic Cancer Clinical Trial | Facebook
TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor | Business
TYME Inc. - Our Science - SM-88 Overview
Tyme Technologies Ceases SM-88 Clinical Trial Due To Drug Failure
Tyme Technologies (TYME.Q) Granted Additional US Patent Claims for Drug Delivery Method, Shares Climb 50% - Equity.Guru
A Trickster Enters the Fight Against Metastatic Cancers - Scientific American
SM-88 for Breast Cancer Clinical Trial | Power
TYME Presents New Preclinical Data Supporting SM-88 Mechanism of Action at AACR 2020 | Business Wire
